Camallergy

Executive Summary

Camallergy is a clinical-stage biopharmaceutical company based in Cambridge, UK, spun out from Cambridge University Hospitals NHS Foundation Trust. The company is dedicated to developing innovative treatments for food allergies, with an initial focus on peanut allergy. Its approach leverages a proprietary medical device designed for precise dosing to improve the safety and efficacy of oral immunotherapy. Camallergy's therapeutic platform aims to address the significant unmet need in food allergy management, where current options are limited. The company's clinical work and real-world treatment service established by its scientific founders provide a strong foundation for its development programs. As a private company, Camallergy is positioned to advance its lead candidate through clinical trials and potentially attract partnerships or further investment to support regulatory approval and commercialization.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data readout for peanut allergy therapy55% success
• Q4 2026Partnership or licensing agreement with a larger pharma company40% success
• Q1 2027Regulatory meeting or guidance from MHRA or FDA on development path70% success